2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3160 Infection predicts impaired hematologic response and increased mortality following immunosuppressive therapy in severe aplastic anemia

Luiz Fernando Bazzo Catto, MD, PhD, Luca Arcuri, MD2, Willian França Costa, MD3, Mary Czech4, Ruba Shalhoub, MS5, Tania R Machado, BSN, RN6, Marília Catto, MD7, Colin Wu, PhD8, Neal Stuart Young, MD9, Jennifer Cuellar-Rodriguez, MD10, Rodrigo T. Calado, MD, PhD11, Bhavisha A Patel, MD12, Emma Groarke, MD13
1 National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
2 National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
3 Universidade de São Paulo, Ribeirao Preto, Brazil
4 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States
5 National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
6 National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
7 Universidade de São Paulo, Ribeirao Preto, Brazil
8 National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
9 National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
10 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States
11 Universidade de São Paulo, Ribeirao Preto, Brazil
12 National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
13 National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States

Background: Infections remain a major cause of morbidity and mortality during the neutropenic period following immunosuppression therapy (IST) for severe aplastic anemia (AA). ASH guidelines recommend antimicrobial prophylaxis in neutropenic AA patients, but supporting evidence is of very low certainty. In this study, we aim to characterize rates and types of infection post-IST in a large cohort of SAA patients and correlate with clinical outcomes and survival.

Methods:  We retrospectively analyzed 277 patients with severe/very severe immune AA (SAA/VSAA) treated with IST (antithymocyte globulin [ATG], cyclosporin, ± eltrombopag [EPAG]) at National Institutes of Health-NIH, USA (n=239) and University of Sao Paulo-USP, Brazil (n=38), from 2013 to 2025. Infections were recorded from first ATG dose until 2 years or secondary events (relapse, second-line treatment, clonal evolution to myeloid neoplasms, or death), whichever occurred first. Infectious events were graded by CTCAE v 6.0; grade ≥3 defined severe infections.

Infections were classified as microbiologically confirmed when a pathogen was identified or clinically defined when based on clinical presentation. Overall survival (OS) at 24 months and at 60 months were estimated by Kaplan-Meier and compared by log-rank test. Cox regression at 24 months evaluated infection burden as a time-varying predictor of mortality. In the NIH cohort, multivariable logistic regression evaluated predictor of hematologic response by 6 months.

Results: Median age was 35 years (IQR: 18-52). VSAA was more common at NIH (43%, vs. 5.3%, P<0.01). EPAG exposure was higher at NIH (87% vs. 29%, P<0.01). Prophylaxis rates (NIH vs. USP) were: antibacterial 2.5% vs. 0%, antiviral 100% vs 18.4% (P<0.01), anti-pneumocystis jirovecii (PCJ) 91.6% vs. 57.9% (pentamidine vs. sulfamethoxazole trimethoprim; P<0.01), antifungal 16.3% vs. 13.2%.

Overall, 343 infectious episodes occurred in 160/277 patients (58%); 78% (n=266) were grade ≥3, affecting 124 patients (45%). USP patients had higher infection rates than NIH (89% vs. 53%, P<0.01) and higher odds of severe infection (OR 11, P<0.01), driven by higher bacterial and fungal infection (FI) rates (66% vs. 26%, P<0.01; 21% vs. 4.6%, P<0.01); viral infection rates were similar (18% vs. 13%, P=0.45). FI also differed qualitatively: NIH, 4 C. albicans, 3 other mold, 1 Aspergillus, 1 Fusarium spp, 1 other yeast, and 1 PCJ; USP, 4 other mold, 3 C. albicans, 1 paracoccidioidomycosis, and 1 PCJ.

Most FI occurred in patients with VSAA (11/19, 57.9%) and in those who had not received antifungal prophylaxis (16/233, 6.9%; median ANC 0.15 x 10^9/L). In contrast, 3/44 patients (6.8%) developed FI on prophylaxis, all presenting with profound neutropenia (median ANC 0.01 x 10^9/L). Overall infection rates were similar between groups (6.8% with prophylaxis vs. 6.9% without), likely reflecting limited statistical power and preferential administration of prophylaxis to patients with deeper baseline neutropenia (median ANC 0.09 vs. 0.39 x10^9/L, P < 0.01).

Severe infection was associated with mortality (log-rank, P<0.01). At 24 months, patients who had ≥3 severe infections had decreased survival (64%) compared to those with 1-2 (99%) or none (98%). A similar pattern was observed regardless of infection classification (all-grade, microbiologically confirmed, or clinically defined). Among microbiologically confirmed infections, a hierarchical classification was applied (fungal ± bacterial ± viral, bacterial ± viral, viral-only, and none), with fungal and bacterial infections associated with higher mortality risk than viral-only or no infection (P<0.01). Cox regression analysis confirmed FI (P= 0.002) as independent predictor of 24-month mortality, independent of age and disease severity.

In the NIH cohort, severe infection was also independently associated with decreased likelihood of achieving hematological response (complete or partial response) by 6 months (OR: 0.19, P = 0.04), as was VSAA (OR 0.32, P < 0.01).

Conclusion: Severe infections independently decrease hematologic response in IST-treated AA, and FI increase 24-month mortality. While practice heterogeneity limited prophylaxis evaluation, most FI occurred either prior to antifungal initiation or as a breakthrough with profound neutropenia, suggesting efficacy in FI prevention.

Luiz Fernando Bazzo Catto, MD, PhD: No relevant conflicts of interest to declare.